echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Biochemistry News > Biotechnology News > Yipinhong's wholly-owned subsidiary obtained the registration certificate of bromhexine hydrochloride injection

    Yipinhong's wholly-owned subsidiary obtained the registration certificate of bromhexine hydrochloride injection

    • Last Update: 2021-09-18
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    On September 15th, Poinsettia issued an announcement stating that its wholly-owned subsidiary Guangzhou Poinsettia had recently received the Drug Registration Certificate for Bromhexine Hydrochloride Injection approved and issued by the State Drug Administration
    .

    According to the approved drug instructions, the company's bromhexine hydrochloride injection is used for patients with chronic bronchitis and other respiratory diseases such as asthma, bronchiectasis, and silicosis who are difficult to cough up when oral administration is difficult
    .

    Bromhexine has a strong phlegm dissolving effect
    .
    It mainly acts on the mucus-producing cells of the trachea and bronchial mucosa, inhibits the synthesis of acidic mucopolysaccharide protein in sputum, and can break the mucin fibers in the sputum, so that the rheological characteristics of trachea and bronchial secretion are restored to normal.
    Reduced, the sputum is diluted and easy to cough up

    .
    At present, bromhexine is included and recommended by many authoritative clinical guidelines, expert consensus and clinical path interpretation at home and abroad

    .
    In 2019, British Thoracic Society Guideline forbronchiectasisinadults was used to remove mucus in the respiratory tract; 2010 "Guidelines for the Diagnosis and Treatment of Sjogren's Syndrome"-used to improve the secretory function of exocrine glands; 2018 Edition "Clinical Pathway Interpretation" Respiratory Diseases Volume-Chronic Bronchitis Expectorant Treatment

    .
    The 2009 Expert Consensus on Children's Respiratory Safety Drugs: Cold and Antipyretic Drugs-Mucus Regulators

    .
    The 2013 Expert Consensus on the Standardized Diagnosis and Treatment of Children's Common Cold in China-Expectorants among common cold medicines commonly used in pediatrics

    .
    2018 pneumoconiosis treats China expert consensus - expectorant treatment

    .

    The approved bromhexine hydrochloride injection is declared according to the new registration classification of chemical drugs in China, and it is deemed to have passed the consistency evaluation
    .
    According to data from Minai.
    com, the new annual sales of bromhexine in domestic urban public and county-level public hospitals will be approximately 1.
    25 billion yuan in 2020

    .

    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Related Articles

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.